Press Room
Eisai Oncology to Present New Research
05/18/2012
Treatment of Refractory Metastatic Renal Cell Carcinoma (RCC) with Lenvatinib (E7080) and Everolimus
Tasquinimod Phase II Overall Survival Data
05/18/2012
Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer.
The Favored Treatment For Kidney Cancer
05/18/2012
The findings will be presented at the American Urological Association's Annual Meeting, May 19 to 23, in Atlanta.
Gender Comparison In Kidney Cancer Surgery
05/18/2012
Henry Ford Hospital researchers who documented these gender differences can't say why they exist.
Treatment trends, vaccine research, prognosis data
05/18/2012
Mount Sinai School of Medicine researchers will present several landmark studies...
Dover-Sherborn PMC Kids Ride honors Bob Freeman
05/18/2012
Bob never got to ride in the PMC. Shortly after registering, he was diagnosed with kidney cancer and was too sick to ride that summer.
Important progress for people with advanced cancers
05/18/2012
"We have made significant progress for people with advanced cancers in the past year," said Hal Barron M.D.
Drugs Show Strong Responses in Critical Cancers
05/18/2012
Bristol-Myers Squibb's (BMS, US) anti-PD-1 candidate BMS-9936558 is showing promise in several cancers, including renal cell carcinoma (RCC).
What lies ahead: Kaylee's battle with cancer
05/18/2012
An area child battling cancer has more to smile about as she completes her latest course of treatment.
News Feed| Powered by NeonCRM |